mRNA COVID-19 Vaccination Sparks Strong Antibody Response in Patients With AML and MDS

Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.

The mRNA COVID-19 vaccine induced a strong antibody response in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), according to observational study results presented during the 2021 ASH Annual Meeting.

Among 46 patients with AML or MDS vaccinated against COVID-19 at Moffitt Cancer Center, 69.6% were seropositive after the first vaccine dose, meaning that COVID-19 markers were found in their blood. This improved to 95.7% after the second vaccine dose, reported Dr. Jeffrey Lancet, at a press briefing delivered during the meeting. Seropositivity indicates that the vaccinated individual is forming antibodies to fight the virus that causes COVID-19.

“Antibody levels increased dramatically following the second vaccine dose, which indicated the potential utility of serial vaccination with good efficacy in poorly responsive patients after the first vaccine dose,” said Lancet, chair of the Department of Hematologic Malignancies at Moffitt Cancer Center.

Antibody titer levels were at a mean of 3,806 after the second vaccine dose, compared with 315 after the first dose, and these levels did not differ between patients with AML or MDS. This difference was observed across different clinical and laboratory variables, including neutropenia, lymphopenia and subsets.

These are promising findings, considering that previous study results have shown that patients with other hematologic malignancies, such as multiple myeloma, may not have as strong responses to the COVID-19 vaccine.

“Patients with myeloid malignancies, including AML and MDS, based on evolving data, are at high risk of severe COVID-19 infection and death,” Lancet said. “Patients with AML and MDS frequently have quantitative and/or qualitative deficiencies of the white blood cells, including the neutrophils and sometimes the lymphocytes as well, as a result of either the disease itself or the treatment of the disease. It’s unclear whether these deficiencies would result in poor immune response to the COVID-19 vaccine, and to date, there has been very little reported on vaccine efficacy amongst patients with AML and MDS.”

The group of patients with AML or MDS in the study were part of a larger study of the immune response to mRNA-1273 vaccination in all patients with cancer. Of the 46 patients with myeloid malignancies included, 32 had AML and 14 had MDS and were, on average, about two years from diagnosis.

The average age at vaccination for the entire group was 68 years. Patients were vaccinated between Jan. 12 to 25, 2021. More than half of the patients were male (58.7%) and 95.7% were White. The median time from diagnosis to the start of vaccination series was 24.3 months, with a range of 4.5 to 105 months.

Fifteen patients were on active treatment for their disease at the time of vaccination. A total of 32 patients (69.6%) had undergone allogeneic stem cell transplantation (SCT) for their disease. Average time since allogeneic SCT for the entire group was 17 months. Forty patients (87%) were in remission at the time of vaccination. Two patients with AML relapsed post-vaccination.

Blood specimens were collected from patients prior to the first and second vaccine doses (days 1 and 29) and approximately 28 days after the second vaccine dose (day 57) for antibody analyses.

The seroconversion rate — which measures the time between exposure/vaccination and the presence of antibodies — was not affected by age, gender, race, disease status, time to vaccination from disease diagnosis, number of prior lines of therapy, receipt of active therapy at the time of vaccination (including targeted therapies), neutrophil and lymphocyte counts, and transplant history, Lancet said.

“In the patients who did not respond to the first vaccine dose, there were suggestions of patients that had either been on steroid therapy or immunosuppression as potential contributing factors to not converting after the first dose, but just about everybody converted after the second dose,” he said.

Antibody levels were significantly higher in patients with solid tumors in the study after the first vaccine dose compared with patients with AML/MDS, but this difference in antibody response disappeared after the second dose, said Dr. Akriti Jain, a hematology/oncology fellow at Moffitt Cancer Center, during the oral abstract presentation.

The most common side effects following vaccination were mild injection site pain (57.5%), fatigue (40%), headache (25%) and arm swelling (27.5%).

Even though therapy prior to vaccination did not affect antibody levels, the few patients on active treatment included in the study is a potential limitation, Lancet explained. In addition, patients on active aggressive therapy (such as BCL-2 inhibitors) were not included because they were not being vaccinated at that time.

The findings need to be confirmed in a larger and more diverse group of patients, the authors concluded.

A version of this article as originally published on OncLive as, “Strong Antibody Response to mRNA COVID-19 Vaccine Observed in AML, MDS.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.